Health Care & Life Sciences » Biotechnology | Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S | Key People and Executives

Michael Thomas Heffernan
Chairman
Lars Kåre Viksmoen
Independent Director
Robert Samuel Radie
Independent Director
Paul Kevin Wotton
Independent Director
Mette Kirstine Agger
Deputy Chairman
Anders Götzsche
Independent Director
Craig A. Collard
President & Chief Executive Officer
Stacy Wheeler
Vice President-Operations
Morten Marott
Chief Financial Officer
Ulf Meier-Kriesche
Chief Scientific Officer
Mark Hensley
Vice President & Head-Sales
Ira Duarte
Vice President-Finance & Controller
Brett Fleshman
VP-Strategy & Corporate Development
Rita L. Mannella
Director-Human Resources
Noel Barnard
Senior Director-Legal
Michael Thomas Heffernan
Chairman
Lars Kåre Viksmoen
Independent Director
Robert Samuel Radie
Independent Director
Paul Kevin Wotton
Independent Director
Mette Kirstine Agger
Deputy Chairman
Anders Götzsche
Independent Director

About Veloxis Pharmaceuticals A/S

View Profile
Address
Amerika Plads 37
Copenhagen CR 2100
Denmark
Employees -
Website http://www.veloxis.com
Updated 07/08/2019
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.